Lifecore Biomedical (LFCR) Q2 FY26 earnings call: guidance and Q&A

When will the expected demand inflection from the largest customer (Alcon) begin in 2027, and will it be immediate or ramped?

The ramp-up will start earlier in 2027, with a slightly heavier weighting towards the back end of the year.

“I would say that it is -- there's -- it starts earlier in '26, I would say, with a slightly heavier weighting on the back end of '27 -- excuse me. So starting early in '27 with a heavier weighting on the back end.”

asked by Matthew Hewitt · answered by Paul Josephs

What are the primary factors contributing to the recent success in securing new business wins, such as reshoring, capacity, or specialized fill/finish capabilities?

New wins are driven by a combination of regionalization of manufacturing, increased FDA enforcement actions (warning letters up ~50% YoY), and the company's strong technical capabilities in the growing injectable market.

“It's the regionalization of manufacturing, but it's also FDA enforcement is up. I mentioned that in my prepared remarks. FDA warning letters are up approximately 50% year-on-year. So we're seeing the benefit of customers looking for high-quality sterile injectable suppliers with strong technical capabilities like Lifecore.”

asked by Matthew Hewitt · answered by Paul Josephs

What is the current status and implications regarding the preferred stock instrument, particularly concerning potential payments?

Any potential payment for the Series A preferred stock would not be due until December 28, would require approval under credit agreements, and any unpaid amounts would accrue interest at 1% per month.

“Our liquidity position is the best it's been in years with the performance and operational improvements that we've made. I think as you think about the Series A preferred, any potential payment, first, would not be due until December 28. We believe that we would also need approval under our credit agreements to make any of those payments. And any outstanding amounts, if not paid, would accrue interest at 1% per month until resolved.”

asked by Paul Knight · answered by Ryan Lake

Is the company targeting a quarterly SG&A expense level of $6 million in the second half of the year, down from current levels?

Yes, the company expects SG&A, excluding one-time items, to trend down to the $6 million per quarter range in the second half of the year.

“And anticipate that SG&A, excluding any onetime items, would be in the $6 million a quarter range.”

asked by Michael Petusky · answered by Ryan Lake

How will the company prepare its employee footprint to service increased customer demand and new business wins in 2027 and beyond?

Minimal incremental indirect/SG&A headcount additions are expected, with leverage over existing staff. The focus will be on adding direct labor and resources to support development efforts, confident in talent acquisition in the Minneapolis-St. Paul area.

“What I would tell you is that certainly, from an indirect and SG&A perspective, we don't expect a significant amount of incremental adds to support the demand. We really believe that we'll be able to get leverage over our existing headcount. There will be some nominal adds in that area. We will, though, spend time and effort in adding resources and potentially different resources to support our development efforts as that continues to grow a bigger and bigger piece of what we do day in, day out, and supporting those projects from development through commercialization.”

asked by Michael Petusky · answered by Paul Josephs

Does the success in securing late-stage and commercial site transfer deals change the company's hurdle rate for new business, potentially making early-stage or smaller deals less attractive?

The ideal customer profile is evolving, with a heavier lean on derisked late-stage and commercial site transfers. While early-phase programs won't be avoided, they will be priced differently due to higher churn rates.

“We've had great success, which now allows it -- we're very humbled by it, but remain very hungry. But as we think about our ideal customer profile, that's beginning to evolve based on our success. And we'll always continue to put a heavier lean on late-stage and commercial site transfers because they are derisked from a commercial standpoint, and this is all about being -- this is a recurring revenue business. But we won't shy away from the early phase programs, but we'll certainly price those maybe a little bit differently, knowing that the success and churn rate is certainly a lot higher than your late-stage or commercial site transfers.”

asked by Michael Petusky · answered by Paul Josephs